1 / 24

Welcome to Oxford Medical Diagnostics

Welcome to Oxford Medical Diagnostics. Company Presentation. Table of Contents. Background. Management. 1. 7. Science Advisory Board. Opportunities. 8. 2. Technologies. Development & Commercial Partners. 3. 9. Product Strategy & Services. Offices. 4. 10. Contact Details.

shauna
Télécharger la présentation

Welcome to Oxford Medical Diagnostics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome to Oxford Medical Diagnostics Company Presentation

  2. Table of Contents Background Management 1 7 Science Advisory Board Opportunities 8 2 Technologies Development & Commercial Partners 3 9 Product Strategy & Services Offices 4 10 Contact Details Target Markets 11 5 Directors 6

  3. A merger of: EV (Medical Screening) – original company Oxford Medical Diagnostics – a former company from the University of Oxford Broadband Cavity Enhanced Absorption Spectroscopy Background

  4. Oxford Medical Diagnostics specialises in the analysis of breath and industrial gases. The Company is developing its patented sensitive and non-invasive methods for the diagnosis of medical conditions by breath analysis. It also has leading knowledge and experience in the detection of gases for industrial applications. Background

  5. Historical Background : An American chemist, peace activist, author, and educator. One of the most influential chemists in history and ranks among the most important scientists of the 20th century. One of the key pioneers of modern breath analysis in the 1970s. Linus Pauling 1901 - 1994

  6. Opportunities : Ammonia – renal diseases Ethane – lipid peroxidation Nitric Oxide – asthma and pulmonary diseases Methane – colonic fermentation and bacterial overgrowth Acetone – Type I and Type II diabetes Detection of Breath Biomarkers

  7. Opportunities : Acetone is a marker for the process of ‘ketogenesis’. It involves the break down of body fat to release energy. This process produces acetone - a volatile, highly blood soluble gas, exchanged in the airways. The ability to detect breath acetone provides a key means for the diagnosis and management of diabetes. Breath Acetone as a Marker for Diabetes

  8. The requirement to analyse industrial gases is ubiquitous across a number of major sectors. Oxford Medical Diagnostics has a range of expertise available for collaborations in Industrial Gas Analysis. Current target gases include: Opportunities : Industrial Gas Analysis

  9. Technologies Plasma Emission Spectroscopy (PES) Cavity Enhanced Absorption Spectroscopy (CEAS) Broadband Cavity Enhanced Absorption Spectroscopy (BB-CEAS) Wavelength Modulation Spectroscopy (WMS)

  10. Technologies : Plasma Emission Spectroscopy (PES) involves the study of light emitted from a high voltage plasma discharge. The discharge is just a few mm across but provides sufficient energy to excite and fragment molecules giving rise to characteristic spectra. Our studies are focused on the visible and near-UV region of the spectrum. Plasma Emissions Spectroscopy

  11. Technologies : Plasma Emission Spectrum of Acetone

  12. Technologies : Cavity Enhanced Absorption Spectroscopy • All molecules absorb light at characteristic frequencies, allowing spectroscopy to be used for identification and quantification. • CEAS utilises two highly-reflective mirrors to give a pathlength of kilometres in a bench-top setup, thus increasing the detection sensitivity. • CEAS can be coupled with a broadband (BB) source to resolve the large spectral features observed in acetone.

  13. Technologies : Cavity Enhanced Absorption Spectroscopy The sensitivity of laser absorption spectroscopy is also limited by noise. This can be reduced by using Wavelength Modulation Spectroscopy (WMS) to move the detection frequency to a less noisy region and thereby increasing the signal to noise ratio.

  14. Product Strategy The Company is developing products for two key areas of the diabetes market: Screening –A bench-top device, based on CEAS technology, for the rapid and cost-effective screening of diabetes and pre-diabetic stages. Monitoring – A handheld device, based on PES technology, for the low-cost, daily monitoring of diabetes. The device could also be used by healthy individuals looking to monitor ‘fat-burning’ through exercise or dieting.

  15. Services Ion Molecule Reaction Mass Spectrometry (IMR-MS) –A pay for service technique, in conjunction with V&F GmbH, which utilises a soft ionisation method to allow the accurate measurement of constituents in a gaseous sample. Collaborations – Opportunities are available in both the Clinical and Industrial Gas Analysis sectors for exclusive commercialisation by partners.

  16. Target Markets • More than 220 million people worldwide have diabetes. This is expected to double by 2030 without intervention. • Whilst the press headlines focus on ‘adult onset’ Type II diabetes, the fastest rising category in percentage terms is Type I diabetes in children. • The daily drawing of blood required for diabetes monitoring is often dreaded by children. A non-invasive alternative would therefore be welcomed by clinicians, parents and their children alike.

  17. Target Market Screening, Diagnosis & Monitoring Global Market £4.6 billion

  18. Routes to Market : Current Global Medical Diagnostic Companies Medical Diagnostics Medical Instrumentation Health Retail

  19. Directors Chairman John Jack (former director IBM UK) Non-executive Seamus Grealish CEO Tony Marchington (former Oxford Molecular) Non-executive Michael O’Higgins CSO Gus Hancock, Professor of Chemistry, University of Oxford Non-executive Peter Copping

  20. Management Company Secretary Rowland Smith Senior Chemist Dr. Grant Ritchie Engineer John Couper Science Director Dr. Robert Peverall PES Development Tom Blaikie BB-CEAS Development David Taylor

  21. Science Advisory Panel Dr. Ewan Bell – Dumfries & Galloway NHS Trust Prof. Albert Crowe – University of Newcastle Prof Gus Hancock, Director of Science & Chairman of the Science Advisory Panel Gus Hancock is Professor of Chemistry, University of Oxford and expert on CEAS and Broadband technologies. Dr. Grant Ritchie – University of Oxford Prof. Fran Ashcroft – University of Oxford

  22. Development & Commercial Partners V&F Analyse und Messtechnik GmbH Uniscan Instruments Avacta Group plc Ocean Optics University of Oxford Dumfries & Galloway Royal Infirmary

  23. The company trades from: The Oxford University Begbroke Science Park, Sandy Lane, Yarnton, Oxford. OX5 1PF INEX, Herschel Building, University of Newcastle, Newcastle upon Tyne. NE1 7RU Offices

  24. Contact Details To learn more about the Company’s technologies, products and services, or to explore the potential for partnership or collaboration please contact: • Telephone: + 44 (0) 1865 854 888 • E-mail: info@omdiagnostics.com • Website: www.omdiagnostics.com

More Related